Data from the end of treatment in the ENRICH study showed increased rates of HBsAg loss, aligning with findings in Cohort 4 of the ENSURE study. This supports the effectiveness of BRII-179 in initiating immune responses for potential functional cure approaches. However, end-of-treatment results from the ENHANCE study did not show significant enhancements in HBsAg loss rates when compared to...